2020-08-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/695142Atrial fibrillation (AF) is a common cardiac arrhythmia and is one of the major causes of ischemic stroke. In addition to the clinical factors such as CHADS2 or CHADS2-VASC score, the impact of genetic factors on the risk of thromboembolic stroke in patients with AF has been largely unknown. Single-nucleotide polymorphisms (SNPs) in several genomic regions have been found to be associated with AF susceptibility. However, whether SNPs in other genomic regions are associated with AF-related thromboembolic stroke are unknown. Therefore, we hypothesize that in addition to CHADS2 or CHADS2-VASC score, genetic factor(s) may help identify AF patients with a higher risk of thromboembolic stroke. We propose a three years’ project to conduct a genome-wide association study (GWAS) using whole genome sequence (WGS) data to identify these genetic factors. In the first and second years, we plan to consecutively recruit AF patients and perform WGS-based subgroup GWAS to identify new genes or loci related to thromboembolic stroke. In the second and third year, we will establish zebrafish, mouse, cellular and induced pluripotent stem cell (iPSC) models to provide a platform for drug testing and investigate the molecular mechanism by which the identified novel genes contribute to AF-related thromboembolic stroke. Our three-year’s project is the first genome-wide WGS SNP study for AF-related thromboembolic stroke and will provide new genetic screen factors to help identify AF patients at risk of thromboembolic stroke and develop novel treatment strategy other than oral anticoagulants.atrial fibrillation； AF-related thromboembolic stroke； whole genome sequence； genome-wide association study； drug testing platform